gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NYSE · EBSHealthcarePharmaceuticals

Emergent Biosolutions, Inc. (EBS)

$5.90−5.60%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$6.25▼ 40.42% in range
Nov 3, 2025Low $4.45 · High $13.90Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Emergent Biosolutions closed at $5.90 on Nov 4, down 5.60%, 57.6% below its 52-week closing high. Volume of 2.3M shares was 2.19× its 20-day average (well above normal).

Split-adjusted performance: -15.1% over one month, -35.2% over six months, -43.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $110M, down 52.4% from a year earlier, with a net margin of -29.7%.

Short interest was 9.7M shares at the Oct 15 settlement, up 4.2% from the prior report (19.3% of float, 9.0 days to cover).

Market cap$302.5M51.3M shares
Revenue · quarter$110.0M−52.4% YoY
Diluted EPS$-0.64−170.3% YoY
P/E · TTM—P/S 0.5×
Net margin-29.7%Gross 26.5%
Dividend yieldNone
52-week range4.45 – 13.90−57.6% from high
Volume2.3M2.19× 20-day avg
Volatility · 60d64.9%Annualised
Short % of float19.3%9.0 days to cover
Net cash-$332.0MCash $175.7M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.8%1M −15.1%3M +11.1%6M −35.2%YTD −52.3%1Y −43.8%3Y +190.6%5Y −87.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum38
Revenue growth22
Net margin51
Value (low P/E)—
Size54

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short9.7M+4.2% vs prior
Days to cover9.0Settled Oct 15
% of float19.3%
Short vol. 10d58.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5M
SPRYARS Pharmaceuticals$3.050.00%−67.1%+114.2%−185.2%—$303.3MCompare
TTRXTurn Therapeutics$9.80+3.05%+158.2%———$297.6MCompare
ARCTArcturus Therapeutics Holdings$10.87+13.94%+19.1%−89.5%−803.8%—$309.0MCompare
CYPHCypherpunk Technologies$2.87+10.38%+154.0%———$309.3MCompare
ENTAEnanta Pharmaceuticals$10.65+2.70%−30.1%−21.6%−135.8%—$310.2MCompare
VOGXVogenx$19.73−3.90%————$293.1MCompare
FULCFulcrum Therapeutics$3.77+0.80%−47.0%———$288.0MCompare
CGCCanopy Growth$0.7517+6.37%−34.6%+7.8%−18.0%—$318.0MCompare

News about Emergent Biosolutions

All news →
Emergent BioSolutions: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · 1d agoNeutralEmergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?Zacks Investment Research · Oct 6, 2026NeutralINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - EBSGlobeNewswire Inc. · Sep 23, 2026▼ NegativeEmergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray MultipacksGlobeNewswire Inc. · Feb 12, 2026▲ Positive

Quick answers

What does Emergent Biosolutions do?
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment.
What is EBS's market cap?
$302.51M, based on the Nov 4 close of $5.90.
Does Emergent Biosolutions pay a dividend?
No regular cash dividend has been paid in the last year.
How much of EBS is sold short?
9.7M shares, 19.3% of float, as of Oct 15, 2026.
What sector is EBS in?
Healthcare, in the Pharmaceuticals industry.

About Emergent Biosolutions

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

HQ: Gaithersburg, MD900 employeesListed Nov 15, 2006emergentbiosolutions.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology